Richard T. Silver

Richard T. Silver's AcademicInfluence.com Rankings

Richard T. Silver

Philosophy

#6816

World Rank

#9919

Historical Rank

Logic

#3921

World Rank

#5151

Historical Rank

philosophy Degrees

Download Badge

Philosophy

Richard T. Silver's Degrees

Doctorate Medicine Columbia University

Why Is Richard T. Silver Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Richard T. Silver's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. (2006) (3337)
European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013. (2013) (1736)
A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis. (2012) (1638)
Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet. (2006) (1300)
Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet. (2009) (1255)
Chronic myeloid leukemia. (1992) (1200)
Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study. (2002) (1068)
Widespread occurrence of the JAK2 V617F mutation in chronic myeloproliferative disorders. (2005) (871)
Philadelphia-negative classical myeloproliferative neoplasms: critical concepts and management recommendations from European LeukemiaNet. (2011) (745)
European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia (2020) (623)
Dasatinib induces notable hematologic and cytogenetic responses in chronic-phase chronic myeloid leukemia after failure of imatinib therapy. (2007) (608)
A phase 2 study of imatinib in patients with relapsed or refractory Philadelphia chromosome-positive acute lymphoid leukemias. (2002) (574)
Arabinosyl cytosine: a useful agent in the treatment of acute leukemia in adults. (1968) (565)
The price of drugs for chronic myeloid leukemia (CML) is a reflection of the unsustainable prices of cancer drugs: from the perspective of a large group of CML experts. (2013) (548)
Cytosine arabinoside with daunorubicin or adriamycin for therapy of acute myelocytic leukemia: a CALGB study. (1982) (508)
Intermittent target inhibition with dasatinib 100 mg once daily preserves efficacy and improves tolerability in imatinib-resistant and -intolerant chronic-phase chronic myeloid leukemia. (2008) (482)
Treatment of acute myelocytic leukemia: a study by cancer and leukemia group B. (1981) (480)
An evidence-based analysis of the effect of busulfan, hydroxyurea, interferon, and allogeneic bone marrow transplantation in treating the chronic phase of chronic myeloid leukemia: developed for the American Society of Hematology. (1999) (414)
JAK2 haplotype is a major risk factor for the development of myeloproliferative neoplasms (2009) (377)
Dasatinib induces durable cytogenetic responses in patients with chronic myelogenous leukemia in chronic phase with resistance or intolerance to imatinib (2008) (363)
Philadelphia chromosome-negative classical myeloproliferative neoplasms: revised management recommendations from European LeukemiaNet (2018) (342)
International Working Group (IWG) consensus criteria for treatment response in myelofibrosis with myeloid metaplasia, for the IWG for Myelofibrosis Research and Treatment (IWG-MRT). (2006) (302)
Primary myelofibrosis (PMF), post polycythemia vera myelofibrosis (post-PV MF), post essential thrombocythemia myelofibrosis (post-ET MF), blast phase PMF (PMF-BP): Consensus on terminology by the international working group for myelofibrosis research and treatment (IWG-MRT). (2007) (297)
Efficacy, safety, and survival with ruxolitinib in patients with myelofibrosis: results of a median 3-year follow-up of COMFORT-I (2013) (287)
Long-term treatment with ruxolitinib for patients with myelofibrosis: 5-year update from the randomized, double-blind, placebo-controlled, phase 3 COMFORT-I trial (2017) (278)
Potent, transient inhibition of BCR-ABL with dasatinib 100 mg daily achieves rapid and durable cytogenetic responses and high transformation-free survival rates in chronic phase chronic myeloid leukemia patients with resistance, suboptimal response or intolerance to imatinib (2010) (250)
TNFα facilitates clonal expansion of JAK2V617F positive cells in myeloproliferative neoplasms. (2011) (214)
Characterization of murine JAK2V617F-positive myeloproliferative disease. (2006) (212)
A clinical-molecular prognostic model to predict survival in patients with post polycythemia vera and post essential thrombocythemia myelofibrosis (2017) (205)
Janus kinase-2 inhibitor fedratinib in patients with myelofibrosis previously treated with ruxolitinib (JAKARTA-2): a single-arm, open-label, non-randomised, phase 2, multicentre study. (2017) (198)
Highly sensitive fluorescence in situ hybridization method to detect double BCR/ABL fusion and monitor response to therapy in chronic myeloid leukemia. (1998) (196)
The revised World Health Organization diagnostic criteria for polycythemia vera, essential thrombocytosis, and primary myelofibrosis: an alternative proposal. (2008) (185)
Combination chemotherapy of advanced diffuse histiocytic lymphoma with the six-drug COP-BLAM regimen. (1982) (183)
Comparison of daily versus intermittent chlorambucil and prednisone therapy in the treatment of patients with chronic lymphocytic leukemia. (1977) (167)
Effect of ruxolitinib therapy on myelofibrosis-related symptoms and other patient-reported outcomes in COMFORT-I: a randomized, double-blind, placebo-controlled trial. (2013) (163)
Prognostic importance of mutations in the ras proto-oncogenes in de novo acute myeloid leukemia (1994) (156)
A comparative study of two regimens of combination chemotherapy in acute leukemia. (1958) (155)
Hodgkin disease survivors at increased risk for problems in psychosocial adaptation (1992) (154)
In Support of a Patient-Driven Initiative and Petition to Lower the High Price of Cancer Drugs. (2015) (139)
Characteristics of the terminal phase of chronic granulocytic leukemia. (1968) (138)
Widespread occurrence of the JAK 2 V 617 F mutation in chronic myeloproliferative disorders (2005) (132)
Recombinant interferon-α may retard progression of early primary myelofibrosis: a preliminary report. (2011) (127)
In vivo two-photon excited fluorescence microscopy reveals cardiac- and respiration-dependent pulsatile blood flow in cortical blood vessels in mice. (2012) (124)
Efficacy of daunorubicin in the therapy of adult acute lymphocytic leukemia: a prospective randomized trial by cancer and leukemia group B. (1984) (124)
Minimal molecular response in polycythemia vera patients treated with imatinib or interferon alpha. (2005) (124)
Long‐term effects of the treatment of polycythemia vera with recombinant interferon‐α (2006) (122)
Myeloproliferative neoplasms and inflammation: whether to target the malignant clone or the inflammatory process or both (2016) (121)
Efficacy, safety and survival with ruxolitinib in patients with myelofibrosis: results of a median 2-year follow-up of COMFORT-I (2013) (115)
Cigarette smoking and risk of acute leukemia: associations with morphology and cytogenetic abnormalities in bone marrow. (1993) (112)
Treatment of early chronic lymphocytic leukemia: Intermittent chlorambucil versus observation (1988) (111)
Daunorubicin in the therapy of acute granulocytic leukemia. (1973) (109)
The effects of postinduction intensification treatment with cytarabine and daunorubicin in adult acute lymphocytic leukemia: a prospective randomized clinical trial by Cancer and Leukemia Group B. (1991) (107)
Interferon and the treatment of polycythemia vera, essential thrombocythemia and myelofibrosis (2013) (105)
Evaluation of WHO criteria for diagnosis of polycythemia vera: a prospective analysis. (2013) (101)
Pegylated Interferon Alfa-2a for Polycythemia Vera or Essential Thrombocythemia Resistant or Intolerant to Hydroxyurea. (2019) (99)
The JAK2 46/1 haplotype predisposes to MPL-mutated myeloproliferative neoplasms. (2010) (96)
The bone marrow in polycythemia vera. (1975) (92)
Fever, rash, and muscle tenderness. A distinctive clinical presentation of disseminated candidiasis. (1978) (86)
Fever, infection and host resistance in acute leukemia. (1958) (85)
Cost-effectiveness of Tyrosine Kinase Inhibitor Treatment Strategies for Chronic Myeloid Leukemia in Chronic Phase After Generic Entry of Imatinib in the United States (2016) (83)
A special fluorescent in situ hybridization technique to study peripheral blood and assess the effectiveness of interferon therapy in chronic myeloid leukemia. (1998) (82)
Four Years of Follow-Up of 1027 Patients with Late Chronic Phase (L-CP), Accelerated Phase (AP), or Blast Crisis (BC) Chronic Myeloid Leukemia (CML) Treated with Imatinib in Three Large Phase II Trials. (2004) (82)
The clinical benefit of ruxolitinib across patient subgroups: analysis of a placebo‐controlled, Phase III study in patients with myelofibrosis (2013) (82)
A loading dose/continuous infusion schedule of fludarabine phosphate in chronic lymphocytic leukemia. (1991) (81)
Comparison of psychosocial adaptation of advanced stage Hodgkin's disease and acute leukemia survivors. Cancer and Leukemia Group B. (1998) (80)
Mitoxantrone in patients with acute leukemia in relapse. (1983) (80)
Comparative study of cytosine arabinoside therapy alone and combined with thioguanine, mercaptopurine, or daunorubicin in acute myelocytic leukemia (1975) (79)
Amplification refractory mutation system, a highly sensitive and simple polymerase chain reaction assay, for the detection of JAK2 V617F mutation in chronic myeloproliferative disorders. (2007) (78)
Prognostic importance of mutations in the ras proto-oncogenes in de novo acute myeloid leukemia. (1994) (77)
Combination chemotherapy for terminal-phase chronic granulocytic leukemia: cancer and leukemia group B studies. (1980) (77)
Long-term effects of the treatment of polycythemia vera with recombinant interferon-alpha. (2006) (77)
A comparison of intermittent vs. continuous and of adriamycin vs. methotrexate 5‐drug chemotherapy for advanced breast cancer A Cancer and Leukemia Group B study (1984) (77)
Recombinant human erythropoietin therapy for anemic cancer patients receiving cisplatin chemotherapy. (1995) (76)
Intensive postremission therapy in adults with acute nonlymphocytic leukemia using various dose schedules of ara-C: a progress report from the CALGB. Cancer and Leukemia Group B. (1987) (75)
Fedratinib in patients with myelofibrosis previously treated with ruxolitinib: An updated analysis of the JAKARTA2 study using stringent criteria for ruxolitinib failure (2020) (72)
Clinical trial of VP 16–213 (NSC 141540) I.V. Twice weekly in advanced neoplastic disease a study by the cancer and leukemia group B (1980) (68)
Pegylated recombinant interferon alpha-2b vs recombinant interferon alpha-2b for the initial treatment of chronic-phase chronic myelogenous leukemia: a phase III study (2004) (68)
Diagnosis and Treatment of Polycythemia Vera and Possible Future Study Designs of the PVSG (2000) (66)
Combination chemotherapy and radiotherapy for acute lymphocytic leukemia in adults: results of CALGB protocol 7113. (1979) (65)
Diagnosis, pathogenesis and treatment of the myeloproliferative disorders essential thrombocythemia, polycythemia vera and essential megakaryocytic granulocytic metaplasia and myelofibrosis. (1999) (64)
Expression of Ia-antigens on normal and chronic myeloid leukemic human granulocyte-macrophage colony-forming cells (CFU-GM) is associated with the regulation of cell proliferation by prostaglandin E. (1982) (64)
The location of breakpoints within the breakpoint cluster region (bcr) of chromosome 22 in chronic myeloid leukemia. (1988) (63)
A new treatment for polycythemia vera: recombinant interferon alfa. (1990) (61)
Management of chronic myeloid leukemia in blast crisis (2015) (59)
Postsurgical adjuvant chemotherapy of stage II breast carcinoma with or without crossover to a non-cross-resistant regimen: a Cancer and Leukemia Group B study. (1996) (59)
Management of CML-blast crisis. (2016) (58)
JAK2(V617F) allele burden in polycythemia vera correlates with grade of myelofibrosis, but is not substantially affected by therapy. (2011) (57)
Quality of life assessment of Hodgkin's disease survivors: a model for cooperative clinical trials. (1990) (56)
JAK2V617F mutational frequency in polycythemia vera: 100%, >90%, less? (2006) (55)
Interferon- 2b: A New Treatment for Polycythemia Vera (1993) (54)
Atypical BCR and ABL D-FISH patterns in chronic myeloid leukemia and their possible role in therapy. (1999) (53)
Interferon alfa: effects of long-term treatment for polycythemia vera. (1997) (53)
Phase I-II trial of mitoxantrone in acute leukemia. (1985) (53)
Imatinib mesylate (GleevecTM) reduces phlebotomy requirements in polycythemia vera (2003) (51)
Risk factors for severe neuropsychiatric toxicity in patients receiving interferon alfa-2b and low-dose cytarabine for chronic myelogenous leukemia: analysis of Cancer and Leukemia Group B 9013. (2000) (51)
The COP-BLAM programs: evolving chemotherapy concepts in large cell lymphoma. (1988) (50)
Importance of bone marrow biopsy in the clinical staging of hodgkin's disease (1970) (50)
JAK2 Mutations are present in all cases of polycythemia vera (2008) (49)
A new effective four‐drug combination of CCNU (1‐[2‐chloroethyl]‐3‐cyclohexyl‐1‐nitrosourea) (NSC‐79038), vinblastine, prednisone, and procarbazine for the treatment of advanced Hodgkin's disease (1980) (47)
Multicenter clinical trial of mitoxantrone in non-Hodgkin's lymphoma and Hodgkin's disease. (1991) (47)
Recombinant interferon-α in myelofibrosis reduces bone marrow fibrosis, improves its morphology and is associated with clinical response (2015) (46)
A new combination chemotherapy for resistant Hodgkin disease. (1977) (45)
Guidelines for protocol studies in chronic lymphocytic leukemia (1978) (45)
PRM-151 in Myelofibrosis: Efficacy and Safety in an Open Label Extension Study (2018) (45)
A comparative trial of daunorubicin, cytosine arabinoside, and thioguanine, and a combination of the three agents for the treatment of acute myelocytic leukemia. (1979) (45)
Comparison of placebo and best available therapy for the treatment of myelofibrosis in the phase 3 COMFORT studies (2014) (44)
Clinical end points for drug treatment trials in BCR-ABL1-negative classic myeloproliferative neoplasms: consensus statements from European LeukemiaNET (ELN) and Internation Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) (2014) (43)
Advances in chemotherapy for large cell lymphoma. (1987) (43)
The neurologic manifestations of the acute leukemias: a clinical study. (1957) (43)
Results of COMFORT-I, a randomized double-blind phase III trial of JAK 1/2 inhibitor INCB18424 (424) versus placebo (PB) for patients with myelofibrosis (MF). (2011) (41)
Results of the Myeloproliferative Neoplasms - Research Consortium (MPN-RC) 112 Randomized Trial of Pegylated Interferon Alfa-2a (PEG) Versus Hydroxyurea (HU) Therapy for the Treatment of High Risk Polycythemia Vera (PV) and High Risk Essential Thrombocythemia (ET) (2018) (41)
The diagnosis of miliary tuberculosis: utility of peripheral blood abnormalities, bone marrow and liver needle biopsy. (1973) (39)
The emergence of Ph-, trisomy -8+ cells in patients with chronic myeloid leukemia treated with imatinib mesylate. (2003) (39)
The role of the mature neutrophil in bacterial infections in acute leukemia. (1957) (38)
Recombinant alpha-2b-interferon in therapy of previously untreated hairy cell leukemia: long-term follow-up results of study by Cancer and Leukemia Group B. (1995) (38)
Interim Analysis of the Myeloproliferative Disorders Research Consortium (MPD-RC) 112 Global Phase III Trial of Front Line Pegylated Interferon Alpha-2a Vs. Hydroxyurea in High Risk Polycythemia Vera and Essential Thrombocythemia (2016) (38)
Interferon-alpha for treating polycythemia vera yields improved myelofibrosis-free and overall survival (2021) (38)
The effect of initial molecular profile on response to recombinant interferon‐α (rIFNα) treatment in early myelofibrosis (2017) (37)
Phase 2 Trial of PRM-151, an Anti-Fibrotic Agent, in Patients with Myelofibrosis: Stage 1 Results (2014) (37)
Recombinant interferon alpha (rIFNα-2b) may retard progression of early primary myelofibrosis (2009) (37)
INFECTIONS, FEVER AND HOST RESISTANCE IN NEOPLASTIC DISEASES. (1963) (37)
PRM-151 in Myelofibrosis: Durable Efficacy and Safety at 72 Weeks (2015) (37)
Driver mutations’ effect in secondary myelofibrosis: an international multicenter study based on 781 patients (2017) (36)
Long-Term Outcome of Ruxolitinib Treatment in Patients with Myelofibrosis: Durable Reductions in Spleen Volume, Improvements in Quality of Life, and Overall Survival Advantage in COMFORT-I (2012) (36)
Stalled cerebral capillary blood flow in mouse models of essential thrombocythemia and polycythemia vera revealed by in vivo two‐photon imaging (2014) (36)
USE OF TESTOSTERONE AND BUSULFAN IN THE TREATMENT OF MYELOFIBROSIS WITH MYELOID METAPLASIA. (1964) (36)
Sustained durability of responses and improved progression-free and overall survival with imatinib treatment for accelerated phase and blast crisis chronic myeloid leukemia: long-term follow-up of the STI571 0102 and 0109 trials (2009) (36)
Peritoneoscopy in Hodgkin disease. Confirmation of results by laparotomy. (1976) (35)
Assessment of Outcomes After Stopping Tyrosine Kinase Inhibitors Among Patients With Chronic Myeloid Leukemia: A Nonrandomized Clinical Trial. (2020) (34)
Strategies that delay or prevent the timely availability of affordable generic drugs in the United States. (2016) (34)
European LeukemiaNet study on the reproducibility of bone marrow features in masked polycythemia vera and differentiation from essential thrombocythemia (2017) (33)
Utility of molecular genetic analysis of bcr rearrangement in the diagnosis of chronic myeloid leukemia. (1987) (33)
Fine mapping of chromosome 22 breakpoints within the breakpoint cluster region (bcr) implies a role for bcr exon 3 in determining disease duration in chronic myeloid leukemia. (1989) (33)
JAK2V617F allele burden is reduced by busulfan therapy: a new observation using an old drug (2013) (33)
A Phase I Study of XL019, a Selective JAK2 Inhibitor, in Patients with Polycythemia Vera (2008) (33)
Morbidity of staging laparotomy in Hodgkin's disease. (1978) (33)
Adoptive immunotherapy for stage IV renal cell carcinoma: a novel protocol utilizing periodate and interleukin-2-activated autologous leukocytes and continuous infusions of low-dose interleukin-2 (1987) (32)
Consistent Benefit of Ruxolitinib Over Placebo in Spleen Volume Reduction and Symptom Improvement Across Subgroups and Overall Survival Advantage: Results From COMFORT-I (2011) (31)
Chronic myeloid leukemia. A perspective of the clinical and biologic issues of the chronic phase. (1990) (30)
Correlation of three methods of measuring cytogenetic response in chronic myelocytic leukemia. (2002) (30)
An Unconventional Antigen Translated by a Novel Internal Ribosome Entry Site Elicits Antitumor Humoral Immune Reactions1 (2006) (30)
Long-Term Outcomes Of Ruxolitinib Therapy In Patients With Myelofibrosis: 3-Year Update From COMFORT-I (2013) (30)
Blastic phase of chronic myeloid leukemia (blCML): a proposal for standardization of diagnostic and response criteria. (1990) (30)
A phase II clinical trial of adoptive immunotherapy for advanced renal cell carcinoma using mitogen-activated autologous leukocytes and continuous infusion interleukin-2. (1989) (30)
Persistent symptoms among survivors of Hodgkin's disease: an explanatory model based on classical conditioning. (2001) (29)
Treatment of adult leukemia with L-asparaginase (NSC-109229). (1971) (29)
Decrease in JAK2V617F allele burden is not a prerequisite to clinical response in patients with polycythemia vera (2012) (29)
Ruxolitinib for myelofibrosis--an update of its clinical effects. (2013) (29)
Interferon alfa in the treatment of Philadelphia-negative chronic myeloproliferative neoplasms. (2011) (28)
Splenectomy in chronic myeloid leukemia. (1978) (28)
Value of molecular monitoring during the treatment of chronic myeloid leukemia: a Cancer and Leukemia Group B study. (1997) (28)
The importance of bone marrow biopsy in the staging of patients with lymphosarcoma. (1973) (27)
Treatment of advanced endometrial carcinoma with doxorubicin and cisplatin: effects on both untreated and previously treated patients. (1985) (27)
The blast phase of chronic myeloid leukaemia. (2009) (27)
Comparative study of 6-chloropurine and 6-mercaptopurine in acute leukemia in adults. (1959) (27)
The treatment of chronic lymphocytic leukemia. (1969) (27)
Examination of platelet function in whole blood under dynamic flow conditions with the cone and plate(let) analyzer: effect of erythrocytosis and thrombocytosis. (2007) (27)
Clinical pharmacology of cytarabine in patients with acute myeloid leukemia: a Cancer and Leukemia Group B study (1995) (26)
Interferon in the treatment of myeloproliferative diseases. (1990) (26)
Dasatinib (SPRYCEL®) in Patients (pts) with Chronic Myelogenous Leukemia in Accelerated Phase (AP-CML) That Is Imatinib-Resistant (im-r) or -Intolerant (im-i): Updated Results of the CA180–005 ’START-A’ Phase II Study. (2006) (26)
Value of cytogenetic abnormalities in post-polycythemia vera and post-essential thrombocythemia myelofibrosis: a study of the MYSEC project (2018) (25)
Novel tumor antigens elicit anti-tumor humoral immune reactions in a subset of patients with polycythemia vera. (2007) (25)
Prognostic significance of additional cytogenetic abnormalities in newly diagnosed patients with Philadelphia chromosome-positive chronic myelogenous leukemia treated with interferon-alpha: a Cancer and Leukemia Group B study. (2004) (23)
Evidence for a New Allele in the Kidd Blood Group System in Indians of Northern Mato Grosso, Brazil (1960) (21)
Appropriate management of polycythaemia vera with cytoreductive drug therapy: European LeukemiaNet 2021 recommendations. (2022) (21)
Intensive postremission therapy in adults with acute nonlymphocytic leukemia with ara-C by continuous infusion or bolus administration: preliminary results of a CALGB phase I study. (1985) (21)
A randomized phase 3 trial of interferon-α vs hydroxyurea in polycythemia vera and essential thrombocythemia (2022) (21)
Comparison of oral melphalan, CCNU, and BCNU with and without vincristine and prednisone in the treatment of multiple myeloma. Cancer and leukemia group B experience (1982) (21)
Jumping translocations of the long arms of chromosome 1 in myeloid malignancies is associated with a high risk of transformation to acute myeloid leukaemia * (2010) (21)
Ex vivo evaluation of erythrocytosis‐enhanced platelet thrombus formation using the cone and plate(let) analyzer: effect of platelet antagonists (2004) (21)
Chemotherapy of the non-Hodgkin's lymphomas. (1976) (20)
Continuous infusion vincristine and bleomycin with high dose methotrexate for resistant non‐Hodgkin's lymphoma (1982) (19)
Densitometric analysis of Southern blot autoradiographs and its application to monitoring patients with chronic myeloid leukemia. (1991) (19)
Some new aspects of modern cancer chemotherapy. (1977) (18)
Dasatinib (D) in patients with accelerated phase chronic myeloid leukemia (AP-CML) who are resistant or intolerant to imatinib: Results of the CA180005 'START-A' study. (2006) (18)
Interferon-alpha 2b: a new treatment for polycythemia vera. (1993) (17)
Mutations with epigenetic effects in myeloproliferative neoplasms and recent progress in treatment: Proceedings from the 5th International Post-ASH Symposium (2011) (17)
Efficacy and Safety Of Fedratinib (SAR302503/TG101348) In Patients With Intermediate- Or High-Risk Myelofibrosis (MF), Post-Polycythemia Vera (PV) MF, Or Post-Essential Thrombocythemia (ET) MF Previously Treated With Ruxolitinib: Interim Results From a Phase II Study (JAKARTA-2) (2013) (17)
Evaluation of aniline mustard in patients with multiple myeloma. (1973) (16)
A prospective evaluation of pegylated interferon alfa-2a therapy in patients with polycythemia vera and essential thrombocythemia with a prior splanchnic vein thrombosis (2019) (16)
High dose methotrexate with citrovorum factor in adult resistant lymphoma (1977) (16)
Impact on MPN Symptoms and Quality of Life of Front Line Pegylated Interferon Alpha-2a Vs. Hydroxyurea in High Risk Polycythemia Vera and Essential Thrombocythemia: Results of Myeloproliferative Disorders Research Consortium (MPD-RC) 112 Global Phase III Trial (2016) (16)
Allogeneic Transplantation for Patients With Advanced Myelofibrosis: Splenomegaly and High Serum LDH are Adverse Risk Factors for Successful Engraftment. (2016) (15)
Anagrelide is effective in treating patients with hydroxyurea-resistant thrombocytosis in patients with chronic myeloid leukemia (2005) (15)
Treatment of polycythemia vera with recombinant interferon alpha (rIFNalpha) or imatinib mesylate. (2005) (15)
Mutiple myeloma resistant to melphalan (NSC-8806) treated with cyclophosphamide (NSC-26271), prednisone (NSC-10023), and chloroquine (NSC-187208). (1975) (15)
Optimal therapy for polycythemia vera and essential thrombocythemia: Preferred use of interferon therapy based on phase 2 trials (2016) (15)
JAK2 Mutations Are Present in All Cases of Polycythemia Vera. (2007) (14)
The Effect of Initial Molecular Profile on Response to Recombinant Interferon Alpha (rIFNα) Treatment in Early Myelofibrosis (2016) (14)
Direct evidence that Bcr-Abl tyrosine kinase activity disrupts normal synergistic interactions between Kit ligand and cytokines in primary primitive progenitor cells. (2003) (14)
Adoptive immunotherapy for stage IV renal cell carcinoma: a novel protocol utilizing periodate and interleukin-2-activated autologous leukocytes and continuous infusions of low-dose interleukin-2. (1988) (14)
Association of Hodgkin disease and Gaucher disease. (1974) (14)
Mediastinal irradiation for chronic lymphocytic leukemia. (1976) (14)
Uncommon or delayed adverse events associated with imatinib treatment for chronic myeloid leukemia. (2010) (14)
Factors associated with prolonged survival in chronic myeloid leukemia (1978) (14)
Clonal immunoglobulin gene rearrangements in chronic lymphocytic leukemia: A correlative study (1988) (14)
Design and rationale for the life after stopping tyrosine kinase inhibitors (LAST) study, a prospective, single-group longitudinal study in patients with chronic myeloid leukemia (2018) (14)
Hydroxyurea and sickle cell crisis. (1995) (14)
Interferon in polycythemia vera and related neoplasms. Can it become the treatment of choice without a randomized trial? (2015) (14)
Treatment of the Chronic Phase of Chronic Myeloid Leukemia with an Intermittent Schedule of Recombinant Interferon Alfa-2b and Cytarabine: Results from CALGB Study 9013 (2003) (14)
A Novel Unconventional Antigen MPD5 Elicits Anti-Tumor Humoral Immune Responses in a Subset of Patients with Polycythemia Vera (2007) (13)
Second primary malignancies in postpolycythemia vera and postessential thrombocythemia myelofibrosis: A study on 2233 patients (2019) (13)
Lymphomatoid Papulosis: Case Report of a Patient Managed with Radiation Therapy and Review of the Literature (1992) (13)
Gender effect on phenotype and genotype in patients with post-polycythemia vera and post-essential thrombocythemia myelofibrosis: results from the MYSEC project (2018) (13)
Distinguishing essential thrombocythemia JAK2V617F from polycythemia vera: limitations of erythrocyte values (2019) (13)
Chronic myeloid leukemia (1992) (12)
The chemotherapy of plasma cell myeloma and related disorders. (1974) (12)
Single agent bevacizumab for myelofibrosis: results of the Myeloproliferative Disorders Research Consortium Trial (2013) (12)
The karyotype of Philadelphia chromosome-negative, bcr rearrangement-positive chronic myeloid leukemia. (1988) (12)
Phenotype variability of patients with post polycythemia vera and post essential thrombocythemia myelofibrosis is associated with the time to progression from polycythemia vera and essential thrombocythemia. (2018) (12)
Ruxolitinib can cause weight gain by blocking leptin signaling in the brain via JAK2/STAT3. (2020) (12)
Combination trial of subcutaneous recombinant alpha 2 b interferon and oral cyclophosphamide in follicular low-grade non-Hodgkin's lymphoma. (1994) (12)
The staging of Hodgkin's disease. Selective vs routine laparotomy. (1973) (12)
Phase 2 trial of PRM-151, an antifibrotic agent, in patients with myelofibrosis: Stage 1 results. (2014) (12)
Morphology of the Blood and Marrow in Clinical Practice (1970) (12)
Associations Between Improvements in Myelofibrosis (MF) Symptoms and Quality of Life Measures with Splenomegaly Reduction in COMFORT-I: A Randomized, Double-Blind, Phase III Trial of the JAK1 and JAK2 Inhibitor Ruxolitinib Versus Placebo in Patients with MF, (2011) (12)
A study of a reduced-intensity conditioning regimen followed by allogeneic stem cell transplantation for patients with hematologic malignancies using Campath-1H as part of a graft-versus-host disease strategy. (2006) (12)
Treatment of polycythemia vera with imatinib mesylate. (2012) (11)
The hematocrit value in polycythemia vera: caveat utilitor (2015) (11)
A randomized trial of CMF versus CMFVP as adjuvant chemotherapy in women with node-positive stage II breast cancer: A CALGB study (1985) (11)
Chronic myeloid leukemia – some topical issues (2007) (11)
Origin of near-haploidy in malignant hematopoietic cells. (1988) (11)
Imatinib Mesylate (GLEEVEC®) Is Effective in the Treatment of Polycythemia Vera: A Multi-Institutional Clinical Trial. (2004) (10)
Imatinib mesylate in polycythemia vera. (2004) (10)
A Special Fluorescent In Situ Hybridization Technique to Study Peripheral Blood and Assess the Effectiveness of Interferon Therapy in Chronic Myeloid Leukemia (1998) (10)
A Special Fluorescent In Situ Hybridization Technique to Study Peripheral Blood and Assess the Effectiveness of Interferon Therapy in Chronic Myeloid Leukemia (1998) (10)
Case 15-2006: the Budd-Chiari syndrome and V617F mutation in JAK2. (2006) (10)
Preliminary safety and efficacy of ruxolitinib in patients (pts) with primary and secondary myelofibrosis (MF) with platelet counts (PC) of 50-100x109/L. (2012) (10)
Ruxolitinib Discontinuation In Patients With Myelofibrosis: An Analysis From Clinical Practice (2013) (10)
Recombinant Interferon Alpha (rIFN) May Retard Progression Of Early Myelofibrosis By Reducing Splenomegaly and By Decreasing Marrow Fibrosis (2013) (9)
Normal life expectancy for polycythemia vera (PV) patients is possible (2021) (9)
Incremental Utility of Right Ventricular Dysfunction in Patients With Myeloproliferative Neoplasm-Associated Pulmonary Hypertension. (2019) (9)
The second international congress on myeloproliferative and myelodysplastic syndromes. (2004) (9)
Evaluation of serum erythropoietin values as defined by 2016 World Health Organization criteria for the diagnosis of polycythemia vera (2017) (8)
Piperazinedione in metastatic renal carcinoma. (1977) (8)
Four-drug combination chemotherapy (methotrexate, cyclophosphamide, hexamethylmelamine, and CCNU) for non-small cell bronchogenic carcinoma: a Cancer and Leukemia Group B study. (1983) (8)
What Is the Most Cost-Effective Strategy for Treating Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia (CML) after Imatinib Loses Patent Exclusivity? (2014) (8)
Results from the U.S. Life after Stopping TKIs (LAST) Study (2017) (8)
Fedratinib Induces Spleen Responses in Patients with Myeloproliferative Neoplasm (MPN)-Associated Intermediate- or High-Risk Myelofibrosis (MF) Resistant or Intolerant to Ruxolitinib: An Updated Analysis of the Phase II JAKARTA2 Study (2019) (8)
Single-Arm Salvage Therapy with Pegylated Interferon Alfa-2a for Patients with High-Risk Polycythemia Vera or High-Risk Essential Thrombocythemia Who Are Either Hydroxyurea-Resistant or Intolerant: Final Results of the Myeloproliferative Disorders-Research Consortium (MPD-RC) Protocol 111 Global Pha (2017) (8)
Adverse events (AEs) and the return of myelofibrosis (MF)-related symptoms after interruption or discontinuation of ruxolitinib (RUX) therapy. (2012) (8)
Response to pegylated interferon in a COVID‐19–positive elderly woman with primary myelofibrosis treated with ruxolitinib (2021) (7)
Fedratinib Improves Myelofibrosis-related Symptoms and Health-related Quality of Life in Patients with Myelofibrosis Previously Treated with Ruxolitinib: Patient-reported Outcomes from the Phase II JAKARTA2 Trial (2021) (7)
A comparative study of dibromomannitol and busulfan in the treatment of chronic myeloid leukemia. A study of cancer and leukemia group B (1987) (7)
Mitoxantrone in acute lymphoblastic leukemia. (1983) (7)
HAC‐cytoxan (cyclophosphamide) chemotherapy for ovarian carcinoma. Alternating Chemotherapy With Intensification (1985) (7)
Patient-Reported Functional Outcomes in Patients with Chronic Myeloid Leukemia after Stopping Tyrosine Kinase Inhibitors. (2021) (7)
Spatial relationship of chromosomes 9 and 22 at metaphase in patients with chronic myelogenous leukemia (CML) (1988) (6)
Recombinant Gamma‐Interferon Has Activity in Chronic Myeloid Leukemia (1990) (6)
Fedratinib (FEDR) in myelofibrosis (MF) patients previously treated with ruxolitinib (RUX): A reanalysis of the JAKARTA-2 study. (2019) (6)
Nitrogen, mineral, uric acid and basal metabolism studies in a case of adult acute leukemia with extensive osteolytic bone disease. (1958) (6)
Treatment of polycythemia vera. (2006) (6)
A New International Multicenter-Based Model to Predict Survival in Myelofibrosis Secondary to Polycythemia and Thrombocythemia: The Mysec Prognostic Model (MYSEC-PM) (2014) (6)
Studies of the plasma proteins in pregnancy using starch gel zone electrophoresis. (1962) (6)
Interferon in Polycythemia Vera (PV) Yields Improved Myelofibrosis-Free and Overall Survival (2019) (6)
The JAK2V617F Mutation Seen in Myeloproliferative Neoplasms (MPNs) Occurs in Patients with Inflammatory Bowel Disease: Implications of a Pilot Study (2013) (6)
Impact of bone marrow fibrosis grade in post‐polycythemia vera and post‐essential thrombocythemia myelofibrosis: A study of the MYSEC group (2019) (6)
A Hope for the Future (2003) (6)
Studies of Serum Protein Abnormalities in Kala Azar.∗ (1961) (6)
Decrease in JAK2V617F Allele Burden is Not a Prerequisite to Clinical Response in Patients with Polycythemia Vera (PV). (2009) (6)
Unusual translocations involving chromosomes 12;22 and 9;12 in a case of chronic myelogenous leukemia. (1985) (6)
Evaluation of tryptophan mustard (NSC-62403) in patients with plasmacytic myeloma. (1967) (5)
New Perspectives of Interferon-alpha2 and Inflammation in Treating Philadelphia-negative Chronic Myeloproliferative Neoplasms (2021) (5)
Intermittent therapy with 6-mercaptopurine (NSC-755) and methotrexate (NSC-740) given intravenously to adults with acute leukemia. (1972) (5)
Length polymorphisms of the human Y chromosome in patients with chronic myelogenous leukemia. (1987) (5)
Phase I / II trial of human recombinant granulocyte-colony-stimulating factor (filgrastim) and escalating doses of cyclophosphamide, mitoxantrone, and 5-FU in the treatment of advanced breast cancer (1999) (5)
Six-drug chemotherapy (hexamethylmelamine, doxorubicin, cisplatin, cyclophosphamide, methotrexate, and 5-FU; CHAMP-5) for ovarian carcinoma: alternating sequences of combination regimens. (1985) (5)
Platelet amino acid levels in essential thrombocytosis. (1966) (5)
Treatment of polycythemia vera with recombinant interferon (2002) (5)
The use of low-dose prednisone and melphalan in the treatment of poor-risk patients with multiple myeloma. (1975) (5)
Evaluation of bone marrow morphology is essential for assessing disease status in recombinant interferon α-treated polycythemia vera patients (2017) (5)
Conference reportThe Third International Congress on Myeloproliferative and Myelodysplastic Syndromes (2007) (4)
Are all interferons the same for therapy in polycythemia vera? (2013) (4)
Prospective Evaluation of the World Health Organization Criteria for the Diagnosis of Polycythemia Vera (2011) (4)
Final Results of Prospective Treatment with Pegylated Interferon Alfa-2a for Patients with Polycythemia Vera and Essential Thrombocythemia in First and Second-Line Settings (2019) (4)
The treatment of essential thromobocytosis revisited. (2011) (4)
Role of heterochromatin during preferential 9q;22q translocation in chronic myelogenous leukemia. (1986) (4)
The JAK2 46/1 Haplotype Predisposes to Myeloproliferative Neoplasms Characterized by Diverse Mutations (2009) (4)
Rearrangement of the breakpoint cluster region (bcr) of chromosome 22 as a diagnostic marker for chronic myeloid leukemia (1988) (4)
Treatment of advanced ovarian carcinoma with hexamethylmelamine, doxorubicin, and cis-platinum (HAC): results in both untreated and previously treated patients. (1984) (4)
A new translocation involving chromosomes 8 and 9 in a Philadelphia-negative chronic myelogenous leukemia. (1988) (4)
Blood Group Studies of Jungle Indians of the Mato Grosso (1962) (3)
Attempted prevention of blast crisis in chronic myeloid leukemia by the use of pulsed doses of cytosine arabinoside and cis-chloronitrosurea during the course of busulfan-maintained remission. (1988) (3)
Patient-Reported Outcome Results from the U.S. Life after Stopping TKIs (LAST) Study in Patients with Chronic Myeloid Leukemia (2019) (3)
Excess Mortality in Young Patients with Myeloproliferative Neoplasms (2021) (3)
Myeloproliferative Neoplasm (MPN) Driver Mutations Are Enriched during Hematopoietic Stem Cell Differentiation in Patterns That Correlate with Clinical Phenotype and Treatment Response (2018) (3)
Value of biopsy in diagnosis of primary lymphosarcoma of marrow. (1977) (3)
Administration of a complex chemotherapy regimen: inpatient versus outpatient treatment. (1983) (3)
Long-term outcomes of ruxolitinib (RUX) therapy in patients (pts) with myelofibrosis (MF): 5-year update from COMFORT-I. (2016) (3)
Myelofibrosis: thalidomide finds a new disease. (2004) (3)
Combination chemotherapy for non-Hodgkin lymphomas: a ten year follow-up study. (1979) (3)
Amplification refractory mutation system (ARMS), a highly sensitive and simple PCR assay for the detection of JAK2 V617F mutation in chronic myeloproliferative disorders (2006) (3)
Recombinant Interferon Alpha (rIFNα) May Retard Progression of Early Primary Myelofibrosis (PM) by Reducing Splenomegaly and by Changing Marrow Morphology. (2008) (3)
Arterial Thrombotic Complications Are Uncommon in Patients without Cardiovascular Risk Factors and Occur at Equivalent Rates in Chronic Myeloid Leukemia (CML) Patients Treated with Imatinib and Nilotinib (2014) (3)
JAK2V617F Mutational Load in Patients with Polycythemia Vera (PV) Measured by Peripheral Blood DNA Is Associated with Disease Severity. (2007) (3)
PS1458 RISK FACTORS AND OUTCOME OF ACUTE MYELOID LEUKEMIA SECONDARY TO POST-POLYCYTHEMIA VERA AND POST-ESSENTIAL THROMBOCYTHEMIA MYELOFIBROSIS: AN ANALYSIS OF THE MYSEC COHORT (2019) (2)
A Novel Machine Learning-Derived Dynamic Scoring System Predicts Risk of Thrombosis in Polycythemia Vera (PV) Patients (2021) (2)
Myeloproliferative disorders: Biology and management (2007) (2)
Prediction of thrombosis in post-polycythemia vera and post-essential thrombocythemia myelofibrosis: a study on 1258 patients (2022) (2)
Update on the treatment of polycythemia vera with recombinant interferon alfa or imatinib mesylate (2007) (2)
Clinical Burden and Progression of Myelofibrosis in a Controlled Study Population of Placebo-Treated Patients (COMFORT-I) (2011) (2)
Position of the Y-chromosome at somatic metaphase in patients with chronic myelogenous leukemia (CML) (1986) (2)
Unusual clonal evolution during blast crisis of chronic myeloid leukaemia (CML) (1994) (2)
Validation of JAK2 and new clinical criteria for the diagnosis of Polycythemia Vera (PV) (2005) (2)
Disappearance of a highly unusual clone, 46,XY,del(7)(p12),t(9;22)(q34;q11) in chronic myeloid leukemia after treatment with recombinant interferon and cytosine arabinoside. (1992) (2)
Combination therapy with interferon and ruxolitinib for polycythemia vera and myelofibrosis: are two drugs better than one? (2020) (2)
Resistance to therapy of acute leukemia developing in the course of polycythemia vera. (1981) (2)
Myelofibrosis: best practices, controversies and 2019 update (2019) (2)
Excess mortality in younger patients with myeloproliferative neoplasms (2022) (2)
Normal Serum-Erythropoietin (S-epo) Level at Diagnosis of Polycythemia Vera (PV) Correlates with LowJAK2V617F Mutant Allele Burden and Indicates Mild Phenotype. (2009) (2)
Comprar Myeloproliferative Disorders: Biology and Management | Ayalew Tefferi | 9781420061628 | Informa Healthcare (2008) (2)
Fedratinib Induces Spleen Responses in Patients with Myeloproliferative Neoplasm-Associated Intermediate- or High-Risk Myelofibrosis (MF) Previously Exposed to Ruxolitinib (RUX), Regardless of Reason for Discontinuing RUX (2019) (2)
Optimal Therapy for Polycythemia Vera and Essential Thrombocythemia: A Different Perspective (2016) (2)
Diagnosis of plasma cell myeloma. (1975) (2)
blood flow in cortical blood vessels in mice reveals cardiac- and respiration-dependent pulsatile In vivo two-photon excited fluorescence microscopy (2012) (2)
Pretreatment Cytogenetic Abnormalities in Polycythemia Vera (PV) Determines the Effectivnes of Imatinib : Studies from a Multi-Institutional Trial. (2004) (1)
Case report: splenectomy in patients with Hodgkin's disease and marrow hypoplasia. (1977) (1)
Leukemianet Recommendations from an expert panel on behalf of the European Evolving concepts in the management of chronic myeloid leukemia. (2011) (1)
COMBINED CLINICAL AND BASIC SCIENCE SEMINAR (1979) (1)
Molecular Biology of CML (2003) (1)
Letter: Acute hemolytic episodes 37 years apart. (1975) (1)
PS1459 FEDRATINIB IN PATIENTS WITH MYELOPROLIFERATIVE NEOPLASM (MPN)-ASSOCIATED MYELOFIBROSIS (MF) PREVIOUSLY TREATED WITH RUXOLITINIB (RUX): A REANALYSIS OF THE PHASE 2 JAKARTA-2 STUDY (2019) (1)
Post-Polycythemia and Post-Thrombocythemia Myelofibrosis Have Distinctive Clinical Phenotypes: An International Multicenter Study on 718 Patients (2014) (1)
Imatinib mesylate is effective in the treatment of polycythemia vera: A multi-institutional clinical trial. (2006) (1)
Hematopoietic fitness of JAK2V617F myeloproliferative neoplasms is linked to clinical outcome (2021) (1)
Correlation of Clinical and Molecular Response to Imatinib in Polycythemia Vera (PV) Patients with Bone Marrow Morphologic and Immunophenotypic Changes. (2006) (1)
Attempted prevention of blast crisis in chronic myeloid leukemia by the use of pulsed doses of cytarabine and lomustine. A Cancer and Leukemia Group B study. (1992) (1)
Polycythemia Vera Patients with >20% Reduction in Whole Blood JAK2V617F Allele Frequency Have Improved Myelofibrosis-Free Survival but Not Overall Survival (2022) (1)
Results from the Myeloproliferative Neoplasm Patient Care Survey: Patient Care Opportunities and Challenges (2018) (1)
Allogeneic Stem Cell Transplantation for Patients with Chronic Myeloid Leukemia After Prior Treatment with Nilotinib or Dasatinib (2010) (1)
Patient- and physician-reported pain after tyrosine kinase inhibitor discontinuation among patients with chronic myeloid leukemia (2022) (1)
Enlarged Spleen Prior to Allogeneic Transplantation for Myelofibrosis Is Associated with Poor Engraftment and Increased Non-Relapse Mortality (2015) (1)
Hematopoietic Stem and Progenitor Cell Fitness As a Novel Prognostic and Monitoring Biomarker for JAK2 V617F Myeloproliferative Neoplasms (MPNs) (2021) (1)
Splenomegaly (SPML) in polycythemia vera (PV): its clinical significance and its relation to symptoms, post-polycythemic myelofibrosis (PPMF) and survival (2022) (1)
Polycythemia vera and other polycythemia syndromes. (2008) (1)
The third International Congress on Myeloproliferative and Myelodysplastic Syndromes. (2007) (1)
Novel Machine Learning Algorithm Predicts Disease Progression in Polycythemia Vera (PV) with Readily-Available Baseline Characteristics (2021) (1)
Hodgkin's disease: value of bone-marrow biopsy. (1968) (1)
Patients' Perspectives on the Definition of Cure in Chronic Myeloid Leukemia: A US Based Survey (2018) (1)
New approaches to the treatment of cancer-related anemia: A panel discussion (1994) (1)
Incidence of Infections and Second Cancers in Philadelphia Chromosome-Negative Patients with Myeloproliferative Neoplasms Treated with Ruxolitinib (2017) (1)
CML Blast Crisis: Implications and Management (2016) (1)
Outcomes in Myelofibrosis Patients Completing 24 and 36 Weeks of Treatment with PRM-151 (2015) (1)
Effect of hematocrit on platelet adhesion under arterial flow conditions (2003) (0)
Antitumor Humoral Immune Reactions Novel Internal Ribosome Entry Site Elicits An Unconventional Antigen Translated by a (2006) (0)
The frequency of the JAK2 V617F mutation in patients with polycythemia vera and its correlation with severity of disease. (2006) (0)
Refractory anemias, pre-leukemia and myelodysplasias. (1985) (0)
Unbiased Identification of Thrombosis Risk Factors in Polycythemia Vera (PV) Using Machine Learning and Rich Data from Automated Extraction of Medical Records Generates Dynamic Models Highly Predictive for Thrombosis in PV (2022) (0)
Monocytes Modulate Megakaryocyte-Mediated Fibrosis of Bone Marrow Stromal Cells in Vitro (2012) (0)
Predisposition for neoplasms in carriers for a constitutional translocation t(11;22)(q23;q11) (1994) (0)
Symptom Burden and Quality of Life in High-Risk Essential Thrombocythemia and Polycythemia Vera Patients Receiving Hydroxyurea or Pegylated Interferon Alfa-2a: Results of Myeloproliferative Neoplasms Research Consortium (MPN-RC) 111 and 112 Trials (2020) (0)
Solid Tumors in Post-Polycythemia Vera and Post-Essential Thrombocythemia Myelofibrosis: A Study on 2220 Patients (2018) (0)
Initial Therapy of Polycythemia Vera (PV) with Interferon Alfa (rIFNa) Compared to Hydroxyurea (HU) or Phlebotomy Only (PHL-O) Is Associated with a Lower Risk of Secondary Myelofibrosis (2018) (0)
Consultations in Molecular Diagnostics Amplification Refractory Mutation System, a Highly Sensitive and Simple Polymerase Chain Reaction Assay, for the Detection of JAK2 V617F Mutation in Chronic Myeloproliferative Disorders (2007) (0)
Design and rationale for the life after stopping tyrosine kinase inhibitors (LAST) study, a prospective, single-group longitudinal study in patients with chronic myeloid leukemia (2018) (0)
A study of a non-myeloablative conditioning regimen followed by allogeneic stem cell transplant (NMT) for patients with hematological malignancies using campath as part of a graft versus host disease (GVHD) strategy. (2004) (0)
the regulation of cell proliferation by prostaglandin E with granulocyte-macrophage colony-forming cells (CFU-GM) is associated Expression of Ia-antigens on normal and chronic myeloid leukemic human (2011) (0)
The Myeloproliferative Disorders and their Treatment with Interferon Alfa (1996) (0)
chronic-phase chronic myeloid leukemia after failure of imatinib therapy Dasatinib induces notable hematologic and cytogenetic responses in (2013) (0)
The ABCCs of myelofibrosis (2005) (0)
Polycythemia vera: aspects of its current diagnosis and initial treatment (2023) (0)
A Novel Mechanism in Generation of Self-Antigen Repertoire - An Unconventional Antigen Translated by a Novel Internal Ribosome Entry Site Elicits Anti-Tumor Humoral Immune Responses. (2006) (0)
leukemia: cancer and leukemia group B studies Combination chemotherapy for terminal-phase chronic granulocytic (2011) (0)
Clinical topics in cancer diagnosis and management (1982) (0)
Cytoreductive surgery. (1984) (0)
Chronic Myeloid Leukemia (CML): A Model Disease for Utilizing Evidence Based Guidelines in a Decade of Progress. (2006) (0)
Development of V617F JAK2 Associated Myeloproliferative Neoplasms Is a Non-Random Event That Is Strongly Dependent on JAK2 Haplotype (2008) (0)
Busulfan Induces Hematologic and Molecular Responses in Polycythemia Vera (PV) Refractory to Multiple Drugs (2012) (0)
Terminal Chronic Myeloid Leukemia (2003) (0)
Predictive value of in vitro mutation data to guide second-generation tyrosine kinase inhibitor selection: ready for prime time? (2011) (0)
Adoptive Immunotherapy for Renal Adenocarcinoma: Use of Oxidizing Mitogen-Treated Mononuclear Leukocytes and Continuous Infusion of Interleukin-2 (1990) (0)
Clinical Phenotype and Genotype Correlations with Time to Progression into Post Polycythemia Vera and Post Essential Thrombocythemia Myelofibrosis (2017) (0)
Jumping Translocations of the Long Arms of Chromosome 1 (1qJT) in Myeloproliferative Neoplasms (MPNs) and Myelodysplastic Syndromes (MDS) Are Associated with High Risk of Transformation to Acute Myelogenous Leukemia (AML). (2009) (0)
Effect of ADP and ATP Receptor Antagonism on Erythrocytosis-Induced Platelet Aggregate Formation under Dynamic Flow Conditions. (2004) (0)
Clinical and Hematologic Characteristics (2003) (0)
A study of a non-myeloablative conditioning regimen followed by allogeneic stem cell transplant (NMT) for patients with hematological malignancies using campath as part of a graft versus host disease (GVHD) strategy (2004) (0)
BONE MARROW ASPIRATION AND BIOPSY. (1965) (0)
Management of CML in 2003 (2003) (0)
Characterization of chromosome 11 with a complex inversion and deletion in an AML [M2] using fluorescence in situ hybridization. (1995) (0)
Comparison of the psychosocial adaptation of survivors of Hodgkin's disease and leukemia (1991) (0)
Chronic myeloid leukemia. (1986) (0)
Recombinant Interferon-α Reduces Thrombotic Events in Patients with Polycythemia Vera (2019) (0)
Blood studies of jungle Indians of the Upper Xingu River, Mato Grosso, Brazil. (1962) (0)
A Novel in Vitro Model of Focal Fibrosis in Bone Marrow Stromal Co-Culture of CD34+ Cells From Patients with Idiopathic Myelofibrosis. (2009) (0)
Fluorescence in Situ Hybridization Test (2003) (0)
In Vivo Imaging of Cerebral Circulation In Mouse Models of Polycythemia Vera (2010) (0)
Evaluation of Bone Marrowmmorphology in Addition to JAK2 Allele Burden Is Essential for Assessing Disease Status in Recombinant Interferon Alpha-Treated Polycythemia Vera Patients (2016) (0)
Life, genes, and death in Ph- MPNs. (2014) (0)
Use of immunoglobulin gene rearrangement to stage disease severity in chronic lymphocytic leukemia (1988) (0)
Splenomegaly (SPML) in Polycythemia Vera (PV): Its Clinical Significance and Relation to Myelofibrosis and Survival (2021) (0)
Influence of testosterone on the development of bone marrow at sites of transplanted bladder mucosa. (1967) (0)
Normal Life Expectancy for Polycythemia Vera Patients Is Possible (2021) (0)
Treatment of Blast Crisis Other than with Imatinib Mesylate (2003) (0)
Gender effect on phenotype and genotype in patients with post-polycythemia vera and post-essential thrombocythemia myelofibrosis: results from the MYSEC project (2018) (0)
Safety of Cytoreductive Therapy in Younger Patients with Polycythemia Vera: A Systematic Review and Meta-Analysis (2022) (0)
Drug shows the potential for long-term relief from a type of chronic leukemia (2021) (0)
CML End Phase and Blast Crisis: Implications and Management (2021) (0)
An International Multicenter Project on Secondary Myelofibrosis (2016) (0)
Is polycythemia vera curable with recombinant interferon alfa (rIFNα) (2016) (0)
Book Review:Atlas of Comparative Primate Hematology. Hans-Jurg Huser (1971) (0)
Tumor Necrosis Factor-Alpha (TNF) Expression Is Elevated in Myelo-Proliferative Neoplasms (MPN) and Modulated by Inhibition of JAK2 V617F. (2009) (0)
769 Electronic cardiac arrest risk triage score as predictor of severe maternal morbidity (2021) (0)
Ruxolitinib Can Lead to Weight Gain in Patients with Myeloproliferative Neoplasms By Uncoupling Feeding from Central Leptin Signaling Via JAK2/STAT3 (2018) (0)
Red cell mass (RCM) determination is essential for proper diagnosis of early stage polycythemia vera (PV) (2012) (0)
Incidence and Epidemiology (2003) (0)
Health-Related Quality of Life (HRQoL) with Fedratinib, a Selective, Oral Inhibitor of Janus Kinase 2 (JAK2), in the Phase II JAKARTA2 Study in Patients with Intermediate- or High-Risk Myelofibrosis Previously Treated with Ruxolitinib (2019) (0)
Telomerase Activity and Telomere Length in Acute and Chronic Leukemia , Pre-and Post-ex Vivo Culture 1 (2000) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Richard T. Silver?

Richard T. Silver is affiliated with the following schools: